外科理论与实践 ›› 2021, Vol. 26 ›› Issue (04): 361-366.doi: 10.16139/j.1007-9610.2021.04.015
茅届齐a, 徐多刚a, 张米粒b, 肖蕴誉c, 明旭a, 李雨哲b, 曹灿b, 于亮b(), 李继坤b(
)
收稿日期:
2021-02-07
出版日期:
2021-07-25
发布日期:
2022-08-02
通讯作者:
于亮,李继坤
E-mail:jkli65975@163.com;liang.yu@shgh.cn
基金资助:
MAO Jieqia, XU Duoganga, ZHANG Milib, XIAO Yunyuc, MING Xua, LI Yuzheb, CAO Canb, YU Liangb(), LI Jikunb(
)
Received:
2021-02-07
Online:
2021-07-25
Published:
2022-08-02
Contact:
YU Liang,LI Jikun
E-mail:jkli65975@163.com;liang.yu@shgh.cn
摘要:
目的:通过分析结肠直肠癌(colorectal cancer, CRC)病人凝血状态和相关临床资料,探索CRC与机体高凝的关系。方法:收集我院胃肠外科2018年8月至2019年12月手术治疗CRC病人的临床病理资料。以术前外周血D-二聚体水平为评估机体高凝状态的指标,回顾性分析影响CRC病人机体高凝状态发生的相关因素。结果:249例中104例(41.8%)术前血清D-二聚体高于正常上限(>550 μg/L)。其中27例(10.8%)术前D-二聚体显著升高(高于正常上限的3倍,即>1 650 μg/L)。术后发生静脉血栓栓塞(venous thromboembolism, VTE)7例。多因素分析显示,肿瘤远处转移及脉管内肿瘤侵犯是术前D-二聚体升高的相关因素。肿瘤远处转移病人与无远处转移的术前D-二聚体异常升高占比分别为73.3%、37.6%(P<0.01)。脉管内肿瘤侵犯者和无脉管内肿瘤侵犯者术前D-二聚体异常升高占比分别为51.9%、34.3%(P<0.01)。按术前D-二聚体分组,正常组、升高组、显著升高组出现肿瘤远处转移的比例分别为2.8%、6.5%、22.2%,病理检查证实的脉管内肿瘤侵犯的比例分别为35.2%、48.1%、66.7%。两个比例都随术前D-二聚体水平升高而上升。3组VTE事件发生率分别为0.7%、3.9%、11.1%。VTE发生率与术前D-二聚体水平呈正相关。结论:肿瘤远处转移及脉管内肿瘤侵犯是导致CRC病人机体高凝状态的重要因素,可作为VTE风险的预测指标。
中图分类号:
茅届齐, 徐多刚, 张米粒, 肖蕴誉, 明旭, 李雨哲, 曹灿, 于亮, 李继坤. 结肠直肠癌病人D-二聚体升高的研究[J]. 外科理论与实践, 2021, 26(04): 361-366.
MAO Jieqi, XU Duogang, ZHANG Mili, XIAO Yunyu, MING Xu, LI Yuzhe, CAO Can, YU Liang, LI Jikun. Study on D-dimer elevation in patients with colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 361-366.
[1] | Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis[J]. PLoS Med, 2012, 9(7): e1001275. |
[2] |
Ades S, Kumar S, Alam M, et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer[J]. J Thromb Haemost, 2015, 13(6):998-1003.
doi: 10.1111/jth.12910 pmid: 25809746 |
[3] |
Blom JW, Vanderschoot JPM, Oostindiër MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study[J]. J Thromb Haemost, 2006, 4(3):529-535.
pmid: 16460435 |
[4] |
Hisada Y, Geddings JE, Ay C, et al. Venous thrombosis and cancer: from mouse models to clinical trials[J]. J Thromb Haemost, 2015, 13(8):1372-1382.
doi: 10.1111/jth.13009 pmid: 25988873 |
[5] | Dai H, Zhou HX, Sun YX, et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer[J]. Biomed Rep, 2018, 9(5):453-457 |
[6] | Lin Y, Liu ZH, Qiu YF, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis[J]. Eur J Surg Onco, 2018, 44(10):1494-1503. |
[7] |
Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer[J]. Hamostaseologie, 2012, 32(2):115-125.
doi: 10.5482/ha-1170 pmid: 21971578 |
[8] |
Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy[J]. Thromb Res, 2010, 126(2):113-118.
doi: 10.1016/j.thromres.2010.05.012 pmid: 20684071 |
[9] |
Falanga A, Schieppati F, Russo L. Pathophysiology 1. mechanisms of thrombosis in cancer patients[J]. Cancer Treat Res, 2019, 179:11-36.
doi: 10.1007/978-3-030-20315-3_2 pmid: 31317478 |
[10] | Menapace LA, Bena J, Morrison S, et al. KRAS mutational status in metastatic colorectal cancer and thrombotic risk[J]. J Clin Oncol, 2017, 35(15 suppl):15140-15146. |
[11] | Ortega L, Garcia P, AguilarI, et al. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status[J]. Clin Trans Onco, 2020, 22(11):2026-2031. |
[12] |
Johnson ED, Schell JC, Rodgers GM, et al. The D-dimer assay[J]. Am J Hematol, 2019, 94(7):833-839.
doi: 10.1002/ajh.25482 pmid: 30945756 |
[13] |
Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations[J]. Proc Natl Acad Sci U S A, 2014, 111(9):3544-3549.
doi: 10.1073/pnas.1314118111 URL |
[14] |
Horstman LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles[J]. Keio J Med, 2004, 53(4):210-230.
doi: 10.2302/kjm.53.210 URL |
[15] |
Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies[J]. J Clin Oncol, 2009, 27(29):4848-4857.
doi: 10.1200/JCO.2009.22.8197 pmid: 19752334 |
[16] |
Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation[J]. J Thromb Haemost, 2008, 6(9):1517-1524.
doi: 10.1111/j.1538-7836.2008.02987.x pmid: 18433463 |
[1] | 孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370. |
[2] | 安宝燕, 郭清, 冯明洋, 徐玉敏, 蔡伟, 谢青, 王晖. aMAP、APRI、FIB-4及肝硬度评估乙型肝炎肝硬化患者食管胃静脉曲张程度的价值探讨[J]. 诊断学理论与实践, 2023, 22(02): 141-146. |
[3] | 韩钰钰 余明薇 王慜 徐媛 陈勇 袁斯明. 体表软组织静脉畸形中局限性血管内凝血的临床特征分析[J]. 组织工程与重建外科杂志, 2022, 18(3): 214-. |
[4] | 李瑞林. 知识翻译学的知识论阐释[J]. 当代外语研究, 2022, 22(1): 47-59. |
[5] | 殷剑光, 宗雅萍, 沈晓卉, 赵敬坤, 陆爱国. 同时性多原发结肠直肠癌治疗与预后分析(附39例报告)[J]. 外科理论与实践, 2022, 27(06): 540-544. |
[6] | 孙艳艳, 兰信堂. 肺癌颅脑转移患者接受放射治疗后前庭功能受损1例[J]. 诊断学理论与实践, 2022, 21(05): 632-634. |
[7] | 戴志强, 郑金鑫, 唐兆庆, 张启, 顾远, 史忠义, 胡国华, 孙益红. 淋巴结转移率对Ⅱ~Ⅲ期胃癌根治术后病人预后的评估[J]. 外科理论与实践, 2022, 27(05): 429-434. |
[8] | 聂明明, 朱正纲. 腹腔镜探查对进展期胃癌精准分期的临床意义[J]. 外科理论与实践, 2022, 27(04): 365-370. |
[9] | 王文涵, 夏蜀珺, 詹维伟. 长链非编码RNA ENST00000489676在超声评估甲状腺乳头状癌颈部淋巴结转移中的应用[J]. 诊断学理论与实践, 2022, 21(04): 514-519. |
[10] | 席锐, 范骎, 王芳, 陶蓉, 顾刚. D-二聚体联合半胱氨酸蛋白酶抑制剂C预测急性心肌梗死患者PCI术后的主要不良心血管事件[J]. 内科理论与实践, 2022, 17(03): 227-232. |
[11] | 徐琛莹, 李嫣然, 倪晓枫, 徐上妍, 林青. 超声预测老年甲状腺乳头状癌患者颈部淋巴结转移的效能及相关超声征象分析[J]. 诊断学理论与实践, 2022, 21(03): 343-348. |
[12] | 包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130. |
[13] | 管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184. |
[14] | 刘荣耀, 李祥翠, 王丽娜, 陈海珍. 甲状腺乳头状癌颈部淋巴结转移的危险因素分析[J]. 外科理论与实践, 2022, 27(01): 76-79. |
[15] | 陈刚, 郑泽宇. 单细胞转录组学分析在胰岛β细胞生理研究中的应用进展[J]. 内科理论与实践, 2021, 16(06): 376-380. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||